treatment-resistant depression

Ketogenic Diet Shows Modest Short-Term Benefits in Treatment-Resistant Depression: A Critical Review of New Clinical Trial Evidence

By MedXY 02/05/2026

A randomized clinical trial finds that a 6-week ketogenic diet provides modest antidepressant effects for treatment-resistant depression compared to a healthy control diet, though long-term clinical relevance and impact on secondary outcomes remain uncertain.

news Psychiatry

ANK3-Guided Liafensine Shows Clinically Meaningful Benefit in Treatment‑Resistant Depression: Results of the ENLIGHTEN Trial

By MedXY 11/14/2025

In ENLIGHTEN, a biomarker-guided randomized trial, ANK3-positive patients with treatment‑resistant depression randomized to liafensine achieved larger MADRS improvements than placebo (mean difference −4.4; 95% CI −7.6 to −1.3; P = .006), with acceptable tolerability.

news Psychiatry Specialties

Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic Frontier

By MedXY 09/11/2025

A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.

Oncology Psychiatry Specialties

Esketamine in Lung Cancer Patients with Major Depression: Efficacy for Smoking Cessation and Treatment-Resistant Depression

By MedXY 08/25/2025

This review synthesizes evidence from a randomized trial and real-world studies showing esketamine's efficacy and safety in smoking cessation among lung cancer patients with MDD, as well as in treatment-resistant depression, highlighting cognitive benefits and long-term safety.

Clinical Updates news Psychiatry Specialties

Pramipexole Augmentation in Treatment-Resistant Unipolar Depression: A UK Multicentre Randomised Trial

By MedXY 08/02/2025

A UK multicentre, double-blind, placebo-controlled trial demonstrates that pramipexole augmentation at 2.5 mg reduces depressive symptoms in treatment-resistant unipolar depression at 12 weeks, with some adverse effects noted, supporting its clinical utility.